

[Members Login](#)[XING Forums](#)[Search](#)[Contact Us](#)[News Channels](#)[Home](#)**CONFERENCES & EVENTS**

[Strategic Marketing and Branding for the Pharmaceutical Industry](#)  
[Workshop on molecular targets for cancer, Bergen, Norway](#)  
[4th Annual Patient Recruitment and Retention in Clinical Trials](#)  
[Jacob Fleming's 4th Annual Enhancing Clinical Trial Processes](#)

[Read more...](#)**RESEARCH & DEVELOPMENT**

[BASF and Transinsight agree to collaborate in exploring alternatives to animal testing](#)  
[ENCITE - European Network for Cell Imaging and Tracking Expertise](#)  
[EMA recommends a new warning for epoetins for their use in cancer patients](#)  
[FDA Revises Process for Responding to Drug Applications](#)

[Read more...](#)**WELCOME**

World Pharma News is an ambitious online news service dedicated to the world pharmaceutical industry. Our main goal is to keep our readers informed about the latest worldwide pharmaceutical news, realizations and achievements.

[Register now](#) to be in touch with our last developments and achievements or [Subscribe to World Pharma News alerts by Email](#) (a free service delivered by FeedBurner).

**Non progredi est regredi.**

Explore the first worldwide Web 2.0 pharmaceutical news portal and 'Vote', 'Comment' or 'Submit' pharmaceutical news articles or other pharmaceutical web resources!

For further information, please visit <http://www.worldpharmanews.net>

**WORLD PHARMA NEWS**.net

Get all news digests delivered to your inbox, subscribe to World Pharma News Google Group.

Email:

**PHARMACEUTICAL COMPANIES**

[\[A\]](#) [\[B\]](#) [\[C\]](#) [\[D\]](#) [\[E\]](#) [\[F\]](#) [\[G\]](#) [\[H\]](#) [\[I\]](#) [\[J\]](#) [\[K\]](#) [\[L\]](#) [\[M\]](#) [\[N\]](#) [\[O\]](#) [\[P\]](#) [\[Q\]](#) [\[R\]](#) [\[S\]](#) [\[T\]](#) [\[U\]](#) [\[V\]](#) [\[W\]](#) [\[X\]](#) [\[Z\]](#)

**PHARMACEUTICAL RSS NEWS**

Start your day with worldwide pharmaceutical news

[\[Amgen\]](#) | [\[AstraZeneca\]](#) | [\[Boehringer Ingelheim\]](#) | [\[Bristol-Myers Squibb\]](#) | [\[GlaxoSmithKline\]](#) | [\[Janssen-Cilag\]](#) | [\[Johnson & Johnson\]](#) | [\[Novartis\]](#) | [\[Novo Nordisk\]](#) | [\[Pfizer\]](#) | [\[Roche\]](#) | [\[Shire\]](#) | [\[Takeda\]](#) |

[European Commission - Pharmaceuticals](#)

[US Food and Drug Administration](#)

sponsored ads

**Pharma Industry News**

Pharma Company News, FDA News Leading Daily Pharma Newsletter  
[www.FiercePharma.com](http://www.FiercePharma.com)

**Global Pharma Jobs**

Regulatory, QA, R&D, Med Comms CRA, Sales, Pharmacovigilance  
[www.pharmalicensing.com/jobs](http://www.pharmalicensing.com/jobs)

**Pharma Markets**

Free Trial to Emerging Markets Analysis & Forecasts Online.  
[www.businessmonitor.com/Pharma](http://www.businessmonitor.com/Pharma)

**Clinical Trial Services**

IATEC, customized research services for the pharmaceutical industry  
[www.iatec.com](http://www.iatec.com)



Web  [www.worldpharmanews.com](http://www.worldpharmanews.com)

sponsored ads

**WORLD PHARMA NEWS .NET / PUBLISHED NEWS**

**[Drug Injury Watch: FDA Needs To Assure Us That There Is Quality Control For Generic Medications Sold In U.S.](#)**

**[BASF and Transinsight agree to collaborate in exploring alternatives to animal testing](#)**

**[ENCITE - European Network for Cell Imaging and Tracking](#)**

**ENCITE - European Network for Cell Imaging and Tracking Expertise**

Monday, 14 July 2008

Researchers define cell therapy as the transplantation of living cells for the replacement or repair of damaged tissue and/or cells. Hot on the heels of stem cell therapy research is a group of leading cell imaging experts who are participating in ENCITE (European network for cell imaging and tracking expertise), a four-year project supported by the EU with €11 million in funding. Coordinated by the Vienna-based European Institute for Biomedical Imaging Research (EIBIR), ENCITE aims to develop imaging technologies and methods in the cell therapy field.

Experts have established three different principles underlying the treatment of medical disorders: (1) transplanted cells used as an 'active drug'; (2) transplanted cells used to replace damaged and degenerated tissue; and (3) cells used as a drug delivery vehicle.

The medical world has been using cell therapy over the years to treat a myriad of disorders, including cancer, spinal cord injuries, autoimmune disorders and Alzheimer's disease. Contrary to what some people may think, cell therapy is not a new concept; one can trace its history to the German-Swiss physician and alchemist, Phillippus Aureolus Paracelsus, who in 1536 theorised that illnesses can be treated with living tissue.

Fast forward to 2008 and it's clear that the medical world lacks a single imaging modality that would be effective in stem cell therapy. But experts say that several types of imaging have the capacity to play major roles in this line of research, particularly magnetic resonance imaging (MRI) and optical imaging. Both these imaging types are being researched by the ENCITE team.

The partners will develop and test innovative MRI imaging methods and biomarkers so as to better understand what happens to a cell and how the immune system responds. The potential impact of ENCITE is that the researchers will break new ground in cell therapy research, as well as strengthen Europe's role in this type of research. Applications of the results can be seen in the treatment of cancer, diabetes and cardiovascular diseases.

ENCITE kicked off last month and comprises 21 partners from 10 countries. Team members say that as ENCITE advances, the collaboration of other highly qualified partners will prove positive for the project. They add that their contribution will strengthen research or dissemination and training activities for the newly developed methods. ENCITE will launch a Competitive Call in autumn 2008 to secure new partners.

The following actions will be taken by ENCITE in order to meet the call and tackle the different cell therapies that exist: (1) deliver new imaging methods to improve the spatio-temporal tracking of labelled cells; (2) establish dual- and multimodality imaging procedures to cross-validate each individual approach; (3) set up new contrast agents and procedures to enhance the sensitivity and specificity of cellular labelling; and (4) combine molecular biology to produce molecular and cellular imaging reporters with multimodal imaging techniques.

ENCITE states that the application of the targeted imaging tools will contribute to raising awareness of cell therapy, response monitoring in patients and treatment safety.

For further information, please visit:  
<http://www.eibir.org>

Copyright ©European Communities, 2008

Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - <http://cordis.europa.eu>. Access to CORDIS is currently available free-of-charge.

**Expertise**

- [Congrats to INSMED...I Think! : Bio Job Blog](#)
- [ACADIA Pharmaceuticals Inc.:Premium Company Profile](#)
- [Accentia Biopharmaceuticals Inc: Premium Company Profile](#)
- [Abbott Laboratories: PharmaVitae Profile](#)
- [EMA recommends a new warning for epoetins for their use in cancer patients](#)
- [Drug Injury Watch: Will There Be An Avelox - Liver Toxicity](#)
- [Warning Letter From Bayer Coming Soon In The U.S., Or Not?](#)
- [FDA Revises Process for Responding to Drug Applications](#)

Bookmark with:



[< Prev](#)

[Next >](#)

[ Back ]

**W** LINK IT!

**OUR RSS NEWS CHANNELS**



sponsored ads

**Clinical Trial Services**

IATEC, customized research services for the pharmaceutical industry  
[www.iatec.com](http://www.iatec.com)

**Pharma Marketing Training**

Intl. Pharma Expert Courses Contact C.E.L.forpharma Now!  
[www.CELforpharma.com](http://www.CELforpharma.com)

**Pharma Approval Trends**

Strategic Market report from URCH on pharma product approvals  
[www.urchpublishing.com](http://www.urchpublishing.com)

**MOST READ - RESEARCH & DEVELOPMENT**

- [The Largest Pharmaceutical Companies and Britain's Serious Fraud Office in the News](#)
- [Study Trends Online Professional Activities and Reveals Specialty-specific Marketing Opportunities](#)
- [New EU Project to Develop a Novel Pandemic Influenza Vaccine](#)
- [The Future of Pharmaceuticals for Human Use in Europe](#)
- [Scientists discover how brain regulates fat metabolism](#)
- [Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates](#)
- [Spending on Cancer Research in Europe Rising](#)
- [European Medicines Agency recommends restricted use of nimesulide-containing medicinal products](#)
- [Putnam Associates Study Finds Insurers Want More Prescription Drug Use](#)
- [EU committee recommends omega-3 supplements during pregnancy](#)

sponsored ads



**World Pharma News**

POWERED BY FEEDBURNER

[↑ Grab this Headline Animator](#)

**PRODUCT**

Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows  
 GlaxoSmithKline responds to FDA on Cervarix® and plans to submit final study data for approval  
 Cervarix™, GSK's cervical cancer vaccine, wins tender for UK national immunisation programme  
 Genzyme Files Applications for Approval of Mozobil in the United States and Europe  
 Romiplostim Data Show Potential Long-Term Efficacy and Safety

[Read more...](#)

**CLINICAL TRIALS**

Novo Nordisk and Neose announce completion of initial phase 1 clinical trial of NN7128  
 Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR  
 Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial  
 Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies  
 International study to evaluate efficacy and safety in treating a leading cause of blindness

[Read more...](#)

**CORPORATE**

Boehringer Ingelheim FENS Award for exceptional research in neuroscience  
 Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case  
 Summary Judgment Granted for SEROQUEL Patent Litigation in the US  
 Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development  
 Abbott and Partnership for a Drug-Free America Launch 'Not In My House'

[Read more...](#)

**FINANCIAL**

Novartis completes acquisition of 25% stake in Alcon from Nestlé  
 Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million  
 Roche's tender offer to increase ownership stake in Chugai successful  
 Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.  
 GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc.

[Read more...](#)